Pretreatment quality-of-life score is a better discriminator of oesophageal cancer survival than performance status

European Journal of Cardio-thoracic Surgery

Volumn 51, Issue 1, 2017, Pages 148-154

  Kidane, Biniam ^a,b   Sulman, Joanne ^a,b   Xu, Wei ^c   Kong, Qin ^c   Wong, Rebecca ^c   Knox, Jennifer J ^c   Darling, Gail E ^a,b,c  

^a UNIVERSITY OF TORONTO   (Canada)

^b TORONTO GENERAL HOSPITAL   (Canada)

^c PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Oesophageal cancer; Performance status; Quality of life; Survival

Indexed keywords

SUNITINIB;

ADULT; AREA UNDER THE CURVE; ARTICLE; CANCER STAGING; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; ESOPHAGUS CANCER; FOLLOW UP; HUMAN; LIKERT SCALE; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; POPULATION RESEARCH; PROSPECTIVE STUDY; QUALITY OF LIFE; RECEIVER OPERATING CHARACTERISTIC; SCORING SYSTEM; WELLBEING; ADENOCARCINOMA; DAILY LIFE ACTIVITY; ESOPHAGEAL NEOPLASMS; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; PATHOLOGY; PROCEDURES; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME;

ACTIVITIES OF DAILY LIVING; ADENOCARCINOMA; CHEMORADIOTHERAPY; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; QUALITY OF LIFE; ROC CURVE; TREATMENT OUTCOME;

EID: 85027988660     PISSN: 10107940     EISSN: 1873734X     Source Type: Journal    
DOI: 10.1093/EJCTS/EZW264     Document Type: Article

References (27)

1. Darling GE. Quality of life in patients with esophageal cancer. Thorac Surg Clin 2013;23:569–75.
2. Safieddine N, Xu W, Quadri SM, Knox JJ, Hornby J, Sulman J et al. Health-related quality of life in esophageal cancer: effect of neoadjuvant chemoradiotherapy followed by surgical intervention. J Thorac Cardiovasc Surg 2009;137:36–42.
3. Gotay CC, Kawamoto CT, Bottomley A, Efficace F. The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol 2008;26:1355–63.
4. Maisey NR, Norman A, Watson M, Allen MJ, Hill ME, Cunningham D. Baseline quality of life predicts survival in patients with advanced colorectal cancer. Eur J Cancer 2002;38:1351–7.
5. Djarv T, Lagergren P. Six-month postoperative quality of life predicts long-term survival after oesophageal cancer surgery. Eur J Cancer 2011;47: 530–5.
6. Djarv T, Metcalfe C, Avery KN, Lagergren P, Blazeby JM. Prognostic value of changes in health-related quality of life scores during curative treatment for esophagogastric cancer. J Clin Oncol 2010;28:1666–70.
7. Blazeby JM, Brookes ST, Alderson D. The prognostic value of quality of life scores during treatment for oesophageal cancer. Gut 2001;49:227–30.
8. Kidane B, Sulman J, Xu W, Kong QQ, Wong R, Knox JJ et al. Baseline measure of health-related quality of life (Functional Assessment of Cancer Therapy-Esophagus) is associated with overall survival in patients with esophageal cancer. J Thorac Cardiovasc Surg 2016;151:1571–80.
9. Hara T, Matsuyama H, Kamiryo Y, Hayashida S, Yamamoto N, Nasu T et al. Use of preoperative performance status and hemoglobin concentration to predict overall survival for patients aged ≥75 years after radical cystectomy for treatment of bladder cancer. Int J Clin Oncol 2016;21:139–47.
10. Erdogan B, Turkmen E, Uzunoglu S, Tanriverdi O, Cicin I. Performance status is an important prognostic factor in second line treatment of pancreaticobiliary adenocarcinoma. Hepatogastroenterology 2013;60:1479–83.
11. Martinez-Salamanca JI, Shariat SF, Rodriguez JC, Chromecki TF, Ficarra V, Fritsche HM et al. Prognostic role of ECOG performance status in patients with urothelial carcinoma of the upper urinary tract: an international study. BJU Int 2012;109:1155–61.
12. Boorjian SA, Kim SP, Tollefson MK, Carrasco A, Cheville JC, Thompson RH et al. Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer. J Urol 2013;190:55–60.
13. Aziz A, Fritsche HM, Gakis G, Kluth LA, Hassan F, Engel O et al. Comparative analysis of comorbidity and performance indices for prediction of oncological outcomes in patients with upper tract urothelial carcinoma who were treated with radical nephroureterectomy. Urol Oncol 2014;32:1141–50.
14. Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer 2006;107:854–63.
15. Knox JJ, Wong R, Visbal AL, Horgan AM, Guindi M, Hornby J et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 2010;116:4023–32.
16. Kidane B, Coughlin S, Vogt K, Malthaner R. Preoperative chemotherapy for resectable thoracic esophageal cancer. Cochrane Database Syst Rev 2015;5:CD001556.
17. Chow E, Abdolell M, Panzarella T, Harris K, Bezjak A, Warde P et al. Predictive model for survival in patients with advanced cancer. J Clin Oncol 2008;26:5863–9.
18. Jang RW, Caraiscos VB, Swami N, Banerjee S, Mak E, Kaya E et al. Simple prognostic model for patients with advanced cancer based on performance status. J Oncol Pract 2014;10:e335–41.
19. Kikuchi N, Ohmori K, Kuriyama S, Shimada A, Nakaho T, Yamamuro M et al. Survival prediction of patients with advanced cancer: the predictive accuracy of the model based on biological markers. J Pain Symptom Manage 2007;34:600–6.
20. Gwilliam B, Keeley V, Todd C, Gittins M, Roberts C, Kelly L et al. Development of Prognosis in Palliative care Study (PiPS) predictor models to improve prognostication in advanced cancer: prospective cohort study. BMJ Support Palliat Care 2015;5:390–8.
21. Kao J, Gold KD, Zarrili G, Copel E, Silverman AJ, Ramsaran SS et al. Clinical predictors of survival for patients with stage IV cancer referred to radiation oncology. PLoS One 2015;10:e0124329.
22. Kawaguchi T, Takada M, Kubo A, Matsumura A, Fukai S, Tamura A et al. Performance status and smoking status are independent favorable prognostic factors for survival in non-small cell lung cancer: a comprehensive analysis of 26,957 patients with NSCLC. J Thorac Oncol 2010;5:620–30.
23. Chau I, Norman AR, Cunningham D, Waters JS, Oates J, Ross PJ. Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer-pooled analysis from three multicenter, randomized, controlled trials using individual patient data. J Clin Oncol 2004;22: 2395–403.
24. Quinten C, Martinelli F, Coens C, Sprangers MA, Ringash J, Gotay C et al. A global analysis of multitrial data investigating quality of life and symptoms as prognostic factors for survival in different tumor sites. Cancer 2014;120: 302–11.
25. Bergquist H, Johnsson A, Hammerlid E, Wenger U, Lundell L, Ruth M. Factors predicting survival in patients with advanced oesophageal cancer: a prospective multicentre evaluation. Aliment Pharmacol Ther 2008;27: 385–95.
26. Blazeby JM, Conroy T, Hammerlid E, Fayers P, Sezer O, Koller M et al. Clinical and psychometric validation of an EORTC questionnaire module, the EORTC QLQ-OES18, to assess quality of life in patients with oesophageal cancer. Eur J Cancer 2003;39:1384–94.
27. McKernan M, McMillan DC, Anderson JR, Angerson WJ, Stuart RC. The relationship between quality of life (EORTC QLQ-C30) and survival in patients with gastro-oesophageal cancer. Br J Cancer 2008;98:888–93.